MA44991A - Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1 - Google Patents

Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1

Info

Publication number
MA44991A
MA44991A MA044991A MA44991A MA44991A MA 44991 A MA44991 A MA 44991A MA 044991 A MA044991 A MA 044991A MA 44991 A MA44991 A MA 44991A MA 44991 A MA44991 A MA 44991A
Authority
MA
Morocco
Prior art keywords
inhibitors
polytherapies
hdac
hdac inhibitors
Prior art date
Application number
MA044991A
Other languages
English (en)
Inventor
Reid P Bissonnette
Mireille Gillings
Alain Rolland
Original Assignee
Huya Bioscience Int Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Bioscience Int Llc filed Critical Huya Bioscience Int Llc
Publication of MA44991A publication Critical patent/MA44991A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MA044991A 2016-05-11 2017-05-11 Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1 MA44991A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335044P 2016-05-11 2016-05-11
US201662436361P 2016-12-19 2016-12-19

Publications (1)

Publication Number Publication Date
MA44991A true MA44991A (fr) 2019-03-20

Family

ID=60267478

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044991A MA44991A (fr) 2016-05-11 2017-05-11 Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1

Country Status (13)

Country Link
US (3) US10385130B2 (fr)
EP (1) EP3454844B1 (fr)
JP (2) JP7013387B2 (fr)
KR (2) KR102469268B1 (fr)
CN (1) CN109562177A (fr)
AU (2) AU2017263478B2 (fr)
BR (1) BR112018073329A2 (fr)
CA (1) CA3023549A1 (fr)
IL (1) IL262814B2 (fr)
MA (1) MA44991A (fr)
MX (2) MX2018013591A (fr)
TW (1) TWI808055B (fr)
WO (1) WO2017197153A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4233546A3 (fr) 2015-05-06 2023-09-27 SNIPR Technologies Limited Modification de populations microbiennes et de microbiotes
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US11033622B2 (en) 2017-05-25 2021-06-15 Leidos, Inc. PD-1 and CTLA-4 dual inhibitor peptides
JOP20200024A1 (ar) 2017-08-04 2020-02-02 Bayer Ag مركبات ثنائي هيدروكساديازينون
EP3661917B1 (fr) 2017-08-04 2022-05-11 Bayer Aktiengesellschaft Dérivés 6-((3-trifluorométhyl)phényl)-4,5-dihydropyridazin-3(2h)-one en tant qu'inhibiteurs de pde3a et pde3b pour le traitement du cancer
SG10201900072VA (en) * 2018-01-05 2019-08-27 Gnt Biotech & Medicals Corp A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
CA3091414A1 (fr) 2018-02-27 2019-09-06 Leidos, Inc. Inhibiteurs peptidiques de pd-1
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
CN117797149A (zh) * 2018-11-20 2024-04-02 深圳微芯生物科技股份有限公司 西达本胺联合r-chop的应用及联合药物
CN109912686B (zh) * 2019-03-13 2022-07-05 北京大学深圳研究生院 一种靶向hdac的稳定多肽类抑制剂及其用途
US11407829B2 (en) 2019-05-22 2022-08-09 Leidos, Inc. LAG3 binding peptides
US20200383961A1 (en) * 2019-06-06 2020-12-10 Huya Bioscience International, Llc Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors
CN112439070A (zh) * 2019-08-28 2021-03-05 深圳微芯生物科技股份有限公司 一种西达本胺药物组合物及其应用
KR20210028339A (ko) * 2019-09-04 2021-03-12 크리스탈지노믹스(주) Hdac 저해제와 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 약학 조성물
US11878009B2 (en) * 2019-09-10 2024-01-23 Great Novel Therapeutics Biotech & Medicals Corporation Anticancer combination of chidamide and celecoxib salts
AU2019465985B2 (en) 2019-09-11 2024-05-02 Great Novel Therapeutics Biotech & Medicals Corporation An anticancer combination of chidamide and celecoxib
WO2021129616A1 (fr) * 2019-12-23 2021-07-01 信达生物制药(苏州)有限公司 Combinaison pharmaceutique d'anticorps anti-pd-1 et d'inhibiteur d'histone désacétylase, son utilisation et son procédé d'utilisation
CN111190006A (zh) * 2020-03-09 2020-05-22 上海市东方医院（同济大学附属东方医院） 组蛋白去乙酰化酶6在制备用于评估维持性腹膜透析患者腹膜功能的标志物中的用途
AU2021283353A1 (en) 2020-06-04 2023-02-02 Leidos, Inc. Immunomodulatory compounds
US11578102B2 (en) 2020-07-31 2023-02-14 Leidos, Inc. LAG3 binding peptides
JP2023539246A (ja) * 2020-08-25 2023-09-13 フヤバイオ インターナショナル，エルエルシー 腫瘍微小環境の遺伝的調節のための方法及び組成物
JP2023548662A (ja) 2020-10-12 2023-11-20 レイドス， インコーポレイテッド 免疫調節性ペプチド
KR20240043709A (ko) * 2022-09-27 2024-04-03 사회복지법인 삼성생명공익재단 히스톤 탈아세틸화효소 억제제를 포함하는 암 치료용 조성물, 및 암 면역치료용 항암 보조제
CN117924505A (zh) * 2024-03-25 2024-04-26 青岛宝迈得生物科技有限公司 一种重组hdac2蛋白单克隆抗体及其应用

Family Cites Families (507)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH627446A5 (fr) 1978-01-17 1982-01-15 Debiopharm Sa Nouveaux derives de la benzamide.
GB8302483D0 (en) 1983-01-29 1983-03-02 Beecham Group Plc Compounds
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
CZ284687B6 (cs) 1986-04-30 1999-02-17 Dainippon Pharmaceutical Co., Ltd. Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0463151B1 (fr) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2529912B2 (ja) 1990-10-16 1996-09-04 帝国化学産業株式会社 ベンズアミド誘導体
US5395832A (en) 1991-02-15 1995-03-07 Hokuriku Seiyaku Co., Ltd. Benzamide derivatives
TW219935B (fr) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
US5610052A (en) 1992-08-26 1997-03-11 Ribozyme Pharmaceuticals Inc. Enzymatic RNA with activity to ras
CA2187429A1 (fr) 1994-04-28 1995-11-09 Junya Ohmori Derive de n-(3-pyrrolidinyl)benzamide
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9525620D0 (en) 1995-12-15 1996-02-14 Glaxo Group Ltd Chemical compounds
EP0827742A1 (fr) 1996-09-04 1998-03-11 Vrije Universiteit Brussel Utilisation des inhibiteurs de l'histone déacétylase pour le traitement de la fibrose ou de la cirrhose
GB9821483D0 (en) 1998-10-03 1998-11-25 Glaxo Group Ltd Chemical compounds
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
EP1500329B1 (fr) 1996-12-03 2012-03-21 Amgen Fremont Inc. Les anticorps humains qui lient en particulier l'alpha de TNF humain
GB9625145D0 (en) 1996-12-03 1997-01-22 Smithkline Beecham Plc Novel compounds
US6444849B1 (en) 1997-06-25 2002-09-03 Mitsubishi Chemical Corporation Amide derivatives
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
US6673827B1 (en) 1999-06-29 2004-01-06 The Uab Research Foundation Methods of treating fungal infections with inhibitors of NAD synthetase enzyme
WO1999059960A1 (fr) 1998-05-15 1999-11-25 Astrazeneca Ab Derives de benzamide servant a traiter des maladies provoquees par des cytokines
ATE272633T1 (de) 1998-12-23 2004-08-15 Lilly Co Eli Aromatische amiden
JP2000256194A (ja) 1999-01-06 2000-09-19 Mitsui Chemicals Inc 核内レセプタ作動薬およびその効果増強剤
US6399627B1 (en) 1999-02-11 2002-06-04 Cor Therapeutics, Inc. Inhibitors of factor Xa
PL350448A1 (en) 1999-03-17 2002-12-16 Astrazeneca Ab Amide derivatives
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
JP4360660B2 (ja) 1999-11-09 2009-11-11 三井化学株式会社 モノアシルフェニレンジアミン誘導体の精製法
WO2001042451A2 (fr) 1999-12-08 2001-06-14 Genset ADNc HUMAINS PLEINE LONGUEUR CODANT POUR DES PROTEINES POTENTIELLEMENT SECRETEES
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6897220B2 (en) 2001-09-14 2005-05-24 Methylgene, Inc. Inhibitors of histone deacetylase
US6706686B2 (en) 2001-09-27 2004-03-16 The Regents Of The University Of Colorado Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
TW200304374A (en) 2001-11-30 2003-10-01 Smithkline Beecham Plc Novel compounds
US7993626B2 (en) 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
US20050215601A1 (en) 2002-09-25 2005-09-29 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatic disease comprising benzamide derivative as active ingredient
US8163896B1 (en) 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US20050054647A1 (en) * 2002-12-27 2005-03-10 Detlev Schuppan New pharmaceutical combination
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
WO2005002626A2 (fr) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Composes de phosphonate therapeutiques
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
US9005613B2 (en) 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
CN1284772C (zh) 2003-07-04 2006-11-15 深圳微芯生物科技有限责任公司 具有分化和抗增殖活性的苯甲酰胺类组蛋白去乙酰化酶抑制剂及其药用制剂
AU2004291062A1 (en) 2003-11-10 2005-06-02 Angiotech International Ag Medical implants and anti-scarring agents
US20130189364A1 (en) 2004-07-09 2013-07-25 Robert Sabin Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
ES2627419T3 (es) 2005-03-04 2017-07-28 Lifescan, Inc. Células estromales adultas derivadas del páncreas
WO2006121518A2 (fr) 2005-05-10 2006-11-16 Angiotech International Ag Dispositifs electriques, agents prevenant la formation de cicatrices et compositions therapeutiques
WO2006135479A2 (fr) 2005-05-10 2006-12-21 Angiotech International Ag Agents anti-cicatrisation, compositions therapeutiques, et leurs utilisations
WO2006121521A2 (fr) 2005-05-10 2006-11-16 Angiotech International Ag Implants pour tissus mous, agents prevenant la formation de cicatrices et compositions therapeutiques
WO2006121522A2 (fr) 2005-05-10 2006-11-16 Angiotech International Ag Capteurs et pompes implantables, agents anticicatrisants, et compositions therapeutiques
US20090247734A1 (en) 2005-12-14 2009-10-01 Hendrickson Wayne A Chemically Derivatized CD4 and Uses Thereof
CA2639070A1 (fr) 2006-04-13 2007-11-01 Oncomethylime Sciences S.A. Nouveau suppresseur de tumeur
US20070292351A1 (en) 2006-05-26 2007-12-20 Methylgene, Inc. Assay for efficacy of histone deacetylase inhibitors
ES2627352T3 (es) 2006-10-19 2017-07-27 Signal Pharmaceuticals, Llc Compuestos heteroarilo, sus composiciones y su uso como inhibidores de proteínas quinasas
EP2170946A2 (fr) 2007-07-13 2010-04-07 The Johns Hopkins University Variants de b7-dc
NZ583351A (en) 2007-08-15 2012-05-25 Cytokinetics Inc Modulate smooth muscle myosin and/or non-muscle myosin
KR20100072024A (ko) 2007-09-14 2010-06-29 메틸진 인크. 히스톤 탈아세틸화 효소 ｈｄａｃ1, ｈｄａｃ2 및/또는 ｈｄａｃ3의 선택적 억제제 및 미세관 안정화제로의 암 병용 치료법
GB0802009D0 (en) 2008-02-04 2008-03-12 Chroma Therapeutics Ltd Biomarkers of aminopeptidase inhibition
JP2009209090A (ja) 2008-03-04 2009-09-17 Mitsui Chemicals Inc 殺虫剤及び該殺虫剤に含まれる化合物、並びに該化合物の使用方法
US9226934B2 (en) 2008-06-02 2016-01-05 The University Of Tokyo Anti-cancer drug
EP2324055A2 (fr) 2008-08-25 2011-05-25 Amplimmune, Inc. Polypeptides cibles co-stimulateurs et methodes pour le traitement du cancer
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US20160041153A1 (en) 2008-11-12 2016-02-11 Kirk Brown Biomarker compositions and markers
CN101757626B (zh) 2008-12-26 2012-12-12 鼎泓国际投资（香港）有限公司 含有胰岛素样生长因子-i受体抑制剂和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN101756957B (zh) 2008-12-26 2012-11-14 鼎泓国际投资（香港）有限公司 含有青蒿素及青蒿素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
CN101837129B (zh) 2009-03-19 2012-12-12 鼎泓国际投资（香港）有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
CN101836989B (zh) 2009-03-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有粉防己碱及粉防己碱类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
WO2011056688A2 (fr) 2009-10-27 2011-05-12 Caris Life Sciences, Inc. Profilage moléculaire pour médecine personnalisée
CA2779424A1 (fr) 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Formulations orales d'inhibiteur de la voie hedgehog
CN102713606A (zh) 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
WO2011063309A1 (fr) 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Procédés et compositions de traitement de cancers associés à hedgehog
EP4289838A3 (fr) 2010-02-11 2024-03-13 Celgene Corporation Dérivés d'arylméthoxy isoindoline substitués, compositions les comportant et procédés d'utilisation associés
NZ602634A (en) 2010-03-26 2015-06-26 Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
KR20130043104A (ko) 2010-04-06 2013-04-29 카리스 라이프 사이언스 룩셈부르크 홀딩스 질병용 순환 생물학적 지표들
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US8993622B2 (en) 2010-06-11 2015-03-31 Eirium Ab Antiviral compounds
US20120010229A1 (en) 2010-07-08 2012-01-12 Macdougall John R Therapeutic regimens for hedgehog-associated cancers
US20120010230A1 (en) 2010-07-08 2012-01-12 Macdougall John R Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2012024543A1 (fr) 2010-08-18 2012-02-23 Caris Life Sciences Luxembourg Holdings Biomarqueurs circulants pour une maladie
CN102441167B (zh) 2010-10-12 2014-05-07 鼎泓国际投资（香港）有限公司 含有芹菜素及芹菜素类衍生物和组蛋白去乙酰化酶抑制剂的药物组合物及其应用
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
US20140141986A1 (en) 2011-02-22 2014-05-22 David Spetzler Circulating biomarkers
WO2012167086A2 (fr) 2011-06-03 2012-12-06 President And Fellows Of Harvard College Méthodes de diagnostic et de traitement d'une sclérose latérale amyotrophique
EP2718721A4 (fr) 2011-06-07 2014-10-01 Caris Life Sciences Luxembourg Holdings S A R L Biomarqueurs circulants pour le cancer
CN103797131A (zh) 2011-06-16 2014-05-14 卡里斯生命科学卢森堡控股有限责任公司 生物标志物组合物和方法
WO2013028907A1 (fr) 2011-08-23 2013-02-28 Infinity Pharmaceuticals, Inc. Biomarqueurs prédictifs de la faculté de réponse thérapeutique à des inhibiteurs de hsp90 et leurs utilisations
WO2013039956A2 (fr) 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement de troubles de l'humeur
JP2014532053A (ja) 2011-09-30 2014-12-04 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 治療用ペプチド
HUE049729T2 (hu) 2011-11-30 2020-10-28 Ludwig Inst For Cancer Res Ltd INKT cella modulátorok és ezek alkalmazásának módszerei
IN2014KN00848A (fr) 2012-02-01 2015-10-02 Compugen Ltd
WO2013124867A1 (fr) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
AU2013229762A1 (en) 2012-03-09 2014-09-25 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
WO2013182660A1 (fr) 2012-06-06 2013-12-12 Bionor Immuno As Vaccin contre le vih
WO2013182661A1 (fr) 2012-06-06 2013-12-12 Bionor Immuno As Peptides issus de protéines virales pour l'utilisation en tant qu'immunogènes et réactifs de dosage
MX2014015830A (es) 2012-06-21 2015-03-05 Compugen Ltd Anticuerpos lsr y usos de los mismos para el tratamiento de cancer.
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
ES2941477T3 (es) 2012-08-13 2023-05-23 Univ Rockefeller Agonista de LXRbeta para el tratamiento de cáncer
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
SG11201501850VA (en) 2012-09-21 2015-04-29 Intensity Therapeutics Inc Method of treating cancer
US20150272980A1 (en) 2012-11-05 2015-10-01 Pronai Therapeutics, Inc. Dosing and Administration of Oligonucleotide Cancer Therapies
AR093512A1 (es) 2012-11-16 2015-06-10 Merck Patent Gmbh Derivados heterociclicos como moduladores de la actividad de cinasas
WO2014082083A1 (fr) 2012-11-26 2014-05-30 Caris Science, Inc. Compositions de biomarqueur et procédés
CN103833626B (zh) 2012-11-27 2015-11-25 深圳微芯生物科技有限责任公司 西达本胺的晶型及其制备方法与应用
BR112015011974A8 (pt) 2012-11-29 2019-10-08 Merck Patent Gmbh derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
KR102356017B1 (ko) 2012-12-13 2022-01-27 이뮤노메딕스, 인코오포레이티드 개선된 효능 및 감소된 독성을 위한 항체 및 sn-38의 면역컨쥬게이트의 투약
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
CN105209068A (zh) 2013-02-07 2015-12-30 免疫医疗公司 用于靶向癌症治疗的缀合至抗体的高效2-吡咯啉多柔比星的前药形式(p2pdox)
WO2014122551A1 (fr) 2013-02-07 2014-08-14 Koninklijke Philips N.V. Système d'éclairage muni d'un contrôleur qui contribue à une lumière d'ambiance sélectionnée et procédé de commande dudit système
CN104056270B (zh) 2013-02-21 2018-11-09 中国人民解放军军事医学科学院野战输血研究所 用于制备多器官损伤救治药物的组蛋白去乙酰化酶抑制剂
CA2903901A1 (fr) 2013-03-05 2014-09-12 Merck Patent Gmbh Derives de 9-(aryl ou heteroaryl)-2-(pyrazolyl, pyrrolidinyl ou cyclopentyl)aminopurine utilises en tant qu'agents anticancereux
AU2014224975B2 (en) 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
ME02917B (fr) 2013-03-14 2018-10-20 Bristol Myers Squibb Co Combinaison d'agoniste de dr5 et d'antagoniste anti-pd-1 et méthodes d'utilisation associées
US9586952B2 (en) 2013-03-14 2017-03-07 Genentech, Inc. Polycyclic estrogen receptor modulators and uses thereof
CN105142668B (zh) * 2013-03-15 2018-04-27 达纳-法伯癌症研究院公司 治疗性肽
EP2970965A2 (fr) 2013-03-15 2016-01-20 Pronai Therapeutics, Inc. Adni pour la modulation de gènes
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CN104069106A (zh) 2013-03-27 2014-10-01 南通瑞思医药技术有限公司 苯甲酰胺类化合物在制备激活潜伏艾滋病病毒药物中的应用
CA2909221A1 (fr) 2013-04-18 2014-10-23 Immune Design Corp. Monotherapie par gla pour une utilisation dans le traitement du cancer
CA2913231A1 (fr) 2013-05-24 2014-11-27 Cooper Human Systems Llc Procedes et compositions pour le traitement d'une infection par le vih
WO2014193999A2 (fr) 2013-05-28 2014-12-04 Caris Science, Inc. Méthodes et compositions d'identification de biomarqueurs
KR20160021277A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조절제 및 이의 용도
JP6389517B2 (ja) 2013-06-19 2018-09-12 セラゴン ファーマシューティカルズ， インク． アゼチジンエストロゲン受容体調節因子及びその使用
JP6599852B2 (ja) 2013-06-21 2019-10-30 ゼニス・エピジェネティクス・リミテッド ブロモドメイン阻害剤としての新規の置換された二環式化合物
WO2015007337A1 (fr) 2013-07-19 2015-01-22 Bionor Immuno As Procédé de vaccination contre le vih
KR20160099081A (ko) 2013-07-26 2016-08-19 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조합 방법
WO2015014446A1 (fr) 2013-07-29 2015-02-05 Merck Patent Gmbh Dérivés de cyclopentane 1,3-disubstitutés
US9751832B2 (en) 2013-07-30 2017-09-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Selective histone deactylase 6 inhibitors
AU2014298051B2 (en) 2013-07-31 2018-11-15 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
LT3027598T (lt) 2013-07-31 2017-06-12 Merck Patent Gmbh Oksochinazolinil-butanamido dariniai
CA2920377A1 (fr) 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition de la signalisation cxr4 en immunotherapie anticancereuse
DK3030554T3 (en) 2013-08-07 2018-06-06 Merck Patent Gmbh PIPERIDINUREADERIVATIVES
US20160201063A1 (en) 2013-08-16 2016-07-14 Rana Therapeutics, Inc. Epigenetic regulators of frataxin
CN103432077A (zh) 2013-08-21 2013-12-11 北京淦航医药科技有限公司 西达苯胺固体分散制剂
WO2015035112A1 (fr) 2013-09-05 2015-03-12 The Johns Hopkins University Thérapie anticancéreuse par l'intermédiaire d'une combinaison de modulation épigénétique et modulation immunitaire
WO2015037000A1 (fr) 2013-09-11 2015-03-19 Compugen Ltd Polypeptides vstm5 et leurs utilisations en tant que médicament pour le traitement du cancer, de maladies infectieuses et de maladies de type immunitaire
EP3043819A4 (fr) 2013-09-11 2017-04-05 Compugen Ltd. Anticorps anti-vstm5 et leur utilisation à des fins thérapeutiques et diagnostiques
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
US20150094518A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Modular polymer platform for the treatment of cancer
JP6684706B2 (ja) 2013-10-21 2020-04-22 ヘモシアー・リミテッド・ライアビリティ・カンパニーＨｅｍｏＳｈｅａｒ， ＬＬＣ 腫瘍微細環境のための試験管内モデル
WO2015061247A2 (fr) 2013-10-21 2015-04-30 Merck Patent Gmbh Composés hétéroaryle servant d'inhibiteurs de la btk et leurs utilisations
US20170080093A1 (en) 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
JP6203954B2 (ja) 2013-10-25 2017-09-27 ノバルティス アーゲー Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体
AU2013404949B2 (en) 2013-11-07 2018-10-18 Deciphera Pharmaceuticals, Llc Methods for inhibiting TIE2 kinase useful in the treatment of cancer
US9457019B2 (en) 2013-11-07 2016-10-04 Deciphera Pharmaceuticals, Llc Methods for inhibiting tie-2 kinase useful in the treatment of cancer
EP3068443B1 (fr) 2013-11-12 2019-04-10 Centre for Probe Development and Commercialization Groupes de liaison à résidualisation et leurs applications
EA201690987A1 (ru) 2013-11-13 2016-10-31 Новартис Аг Низкодозовые иммуностимулирующие ингибиторы mtor и их применения
WO2015074081A1 (fr) 2013-11-18 2015-05-21 Bair Kenneth W Compositions de benzopipérazine en tant qu'inhibiteurs de bromodomaines bet
BR122019007990B1 (pt) 2013-11-18 2021-05-04 Forma Therapeutics, Inc Composto, e, composição farmacêutica
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
JP6705746B2 (ja) 2013-12-06 2020-06-03 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 治療用ペプチド
WO2015086738A2 (fr) 2013-12-11 2015-06-18 Bionor Immuno As Vaccin contre le vih
WO2015089380A2 (fr) 2013-12-12 2015-06-18 Celcuity Llc Tests et procédés pour déterminer la sensibilité d'un sujet individuel à un agent thérapeutique
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
MY193649A (en) 2013-12-20 2022-10-21 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
MX2016008013A (es) 2013-12-23 2017-05-12 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
RS56746B1 (sr) 2013-12-23 2018-03-30 Merck Patent Gmbh Imidazopirazinon derivati
EP3091970B1 (fr) 2014-01-10 2020-10-28 Rgenix, Inc. Agonistes du récepteur x du foie et leurs utilisations
CN104771363A (zh) 2014-01-14 2015-07-15 深圳微芯生物科技有限责任公司 一种西达本胺固体分散体及其制备方法与应用
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
WO2015110659A1 (fr) 2014-01-27 2015-07-30 Bionor Immuno As Méthodes d'immunisation avec un vaccin induisant une réponse immunitaire humorale et avec un vaccin induisant une réponse immunitaire cellulaire
US10143737B2 (en) 2014-01-27 2018-12-04 Bionor Pharma Asa Method for the vaccination against HIV
CA2936335A1 (fr) 2014-01-27 2015-07-30 Bionor Immuno As Schema posologique d'un vaccin contre le vih
US9631013B2 (en) 2014-01-28 2017-04-25 Fibrogen, Inc. Therapeutic method for pancreatic cancer
CA2937989A1 (fr) 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Isothiazoles amino-substitues
WO2015113927A1 (fr) 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Isothiazoles amino-substitués
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US10619210B2 (en) 2014-02-07 2020-04-14 The Johns Hopkins University Predicting response to epigenetic drug therapy
EP3110794A1 (fr) 2014-02-27 2017-01-04 Merck Patent GmbH Composés hétérocycliques en tant qu'inhibiteurs du canal nav, et leurs utilisations
JP2017513812A (ja) 2014-02-28 2017-06-01 ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ 免疫療法用のａｐｃ活性剤としてのｔｃ−ｐｔｐ阻害剤
EP3119908A4 (fr) 2014-03-11 2018-02-21 The Council Of The Queensland Institute Of Medical Research Détermination de l'agressivité d'un cancer, de son pronostic et de sa sensibilité à un traitement
BR112016020953A2 (pt) 2014-03-13 2018-01-23 Hoffmann La Roche composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção
US20150258080A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic combinations with estrogen receptor modulators
AU2015229103C9 (en) 2014-03-14 2020-11-26 Immutep S.A.S Antibody molecules to LAG-3 and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
CN104974079A (zh) 2014-04-02 2015-10-14 C&C生物医药有限公司 苯胺相关化合物的酰胺衍生物及其组合物
UY36060A (es) 2014-04-02 2015-10-30 Bayer Pharma AG Compuestos de azol sustituidos con amida
WO2015153948A2 (fr) 2014-04-03 2015-10-08 University Of Maryland, Baltimore Imagerie de microtentacule d'échantillons de tumeur d'un patient
CN103880736B (zh) 2014-04-04 2017-05-17 深圳微芯生物科技有限责任公司 一种e构型苯甲酰胺类化合物及其药用制剂与应用
WO2015157162A1 (fr) * 2014-04-06 2015-10-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Histone désacétylase comme modulateur de l'expression et de l'activité de pdl1
EP3129367B1 (fr) 2014-04-08 2019-09-04 Rigel Pharmaceuticals, Inc. Composés de pyridine 2,3-disubstitués utilisés comme inhibiteurs de tgf-bêta
NO2776305T3 (fr) 2014-04-23 2018-01-27
JP2015209376A (ja) 2014-04-24 2015-11-24 国立大学法人北海道大学 腫瘍特異的免疫増強剤
ES2885451T3 (es) 2014-04-30 2021-12-13 Inspirna Inc Inhibidores del transporte de creatina y usos de los mismos
WO2015168614A2 (fr) 2014-05-01 2015-11-05 Board Of Regents Of The University Of Nebraska Compositions polymères d'inhibiteurs de l'histone déacétylase et leurs méthodes d'utilisation
WO2015172747A1 (fr) 2014-05-16 2015-11-19 Zhaoyin Wang Molécules spirocycliques servant d'inhibiteurs de mth1
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2015184405A1 (fr) 2014-05-30 2015-12-03 Medivation Technologies, Inc. Composés aromatiques, compositions et utilisations correspondantes
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
TW202134236A (zh) 2014-06-12 2021-09-16 美商西爾拉癌症醫學公司 N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
SG11201609877XA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
JP2017522274A (ja) 2014-06-13 2017-08-10 ギリアード サイエンシーズ， インコーポレイテッド ホスファチジルイノシトール３−キナーゼ阻害剤
EP3154961B1 (fr) 2014-06-13 2019-10-09 Gilead Sciences, Inc. Dérivés de quinazolinone utilisés comme inhibiteurs de la phosphatidylinositol 3-kinase
SG11201610095SA (en) 2014-06-13 2016-12-29 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
CA2952044C (fr) 2014-06-13 2019-01-29 Gilead Sciences, Inc. Inhibiteurs de la phosphatidylinositol 3-kinase
CA2987978C (fr) 2014-06-16 2022-08-16 Fundacion Para La Investigacion Medica Aplicada Nouveaux composes utilises comme inhibiteurs doubles d'histone methyltransferases et d'adn methyltransferases
US10428044B2 (en) 2014-06-17 2019-10-01 Bayer Pharma Aktiengesellschaft 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr) 2014-06-20 2018-06-23
MX2016017110A (es) 2014-06-24 2017-05-01 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-cinasa.
CN106659772B (zh) 2014-06-26 2021-08-31 耶鲁大学 在疾病和紊乱的治疗中调节肾酶的组合物和方法
EP3166633A1 (fr) * 2014-07-11 2017-05-17 Bionor Immuno AS Procédé permettant de réduire et/ou de retarder les effets pathologiques du virus de l'immunodéficience humaine i (vih) ou de réduire le risque de développer le syndrome d'immunodéficience acquise (sida)
MX2017000026A (es) 2014-07-11 2017-05-01 Gilead Sciences Inc Moduladores de receptores tipo toll para el tratamiento de virus de inmunodeficiencia humana (vih).
EP3169326B1 (fr) 2014-07-15 2021-03-31 The Johns Hopkins University Suppression de cellules suppressives d'origine myéloïde et blocage de point de contrôle immunitaire
CN104083763A (zh) 2014-07-16 2014-10-08 中国人民解放军军事医学科学院野战输血研究所 组蛋白去乙酰化酶抑制剂在制备潜伏病毒激活剂中的应用
JP2017522324A (ja) 2014-07-17 2017-08-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用
WO2016014890A1 (fr) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Traitement du myélome multiple avec des inhibiteurs hétérocycliques de la glutaminase
EP3172204A1 (fr) 2014-07-25 2017-05-31 Bayer Pharma Aktiengesellschaft Isoxazoles amino-substitués
EP3174974B1 (fr) 2014-07-29 2020-05-20 Novartis AG Régimes d'escalade de dose d'hétérodimère il-15 et il-15 r-alpha pour traiter des troubles
TWI656121B (zh) 2014-08-04 2019-04-11 德商拜耳製藥公司 ２－（嗎啉－４－基）－１，７－萘啶
WO2016022955A1 (fr) 2014-08-07 2016-02-11 Mayo Foundation For Medical Education And Research Composés et méthodes de traitement du cancer
GB201414464D0 (en) 2014-08-14 2014-10-01 Technion Res & Dev Foundation Compositions and methods for therapeutics prescreening
ES2732026T3 (es) 2014-08-18 2019-11-20 Ono Pharmaceutical Co Sal de adición de ácido de un compuesto inhibidor de Trk
EP3597176A1 (fr) 2014-08-19 2020-01-22 The Regents Of The University Of California Implants pour administration localisée de médicaments et leurs procédés d'utilisation
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CA2993462A1 (fr) 2014-08-26 2016-03-03 Fundacion Para La Investigacion Medica Aplicada Produits pour le traitement et la prevention de troubles neurologiques ayant lieu conjointement avec un deficit ou un dysfonctionnement cognitif, et de maladies neurodegeneratives
WO2016033243A1 (fr) 2014-08-29 2016-03-03 Gilead Sciences, Inc. Agents antirétroviraux
US20160067255A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EP3925622A1 (fr) 2014-09-13 2021-12-22 Novartis AG Polythérapies
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
AP2017009803A0 (en) 2014-09-19 2017-03-31 Bayer Pharma AG Benzyl substituted indazoles as bub1 inhibitors
JP2017529353A (ja) 2014-09-19 2017-10-05 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類
EP3194378A1 (fr) 2014-09-19 2017-07-26 Bayer Pharma Aktiengesellschaft Indazoles à substituants benzyle
KR20170090408A (ko) 2014-09-19 2017-08-07 매카이 메디컬 파운데이션 더 프레즈비티리언 처치 인 타이완 매카이 메모리얼 호스피탈 벤조-헤테로시클릭 화합물 및 이의 적용
JP2017535514A (ja) 2014-09-19 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト Ｂｕｂ１キナーゼ阻害薬としてのベンジル置換インダゾール類
ES2964769T3 (es) 2014-09-24 2024-04-09 Exscientia Gmbh Monocapa de PBMC o células de médula ósea y usos de la misma
CN104725628B (zh) 2014-10-01 2018-04-17 厦门赛诺邦格生物科技股份有限公司 一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
CN104530413B (zh) 2014-10-01 2017-08-25 厦门赛诺邦格生物科技股份有限公司 一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
CN104530415B (zh) 2014-10-01 2017-09-01 厦门赛诺邦格生物科技股份有限公司 一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
US20170209574A1 (en) 2014-10-03 2017-07-27 Novartis Ag Combination therapies
KR102523111B1 (ko) 2014-10-06 2023-04-18 메르크 파텐트 게엠베하 Btk 억제제로서 헤테로아릴 화합물 및 이들의 용도
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
WO2016061087A1 (fr) 2014-10-14 2016-04-21 The Usa, As Represented By The Secretary, Dept. Of Health & Human Services Méthodes de traitement du cancer du pancréas reposant sur l'administration de peptides
WO2016061495A1 (fr) 2014-10-16 2016-04-21 Predictive Therapeutics Ltd. Systèmes et procédés ataviques de découverte de biomarqueurs
US10889812B2 (en) 2014-10-24 2021-01-12 University Of Maryland, Baltimore Short non-coding protein regulatory RNAs (sprRNAs) and methods of use
WO2016066634A2 (fr) 2014-10-27 2016-05-06 Ruprecht-Karls-Universität Heidelberg Utilisation d'antagonistes du ccr5 en monothérapie ou en polythérapie pour le traitement du cancer
RU2695521C9 (ru) 2014-10-30 2019-08-19 Канпу Биофармасьютикалс, Лтд. Производное изоиндолина, промежуточный продукт, способ получения, фармацевтическая композиция и ее применение
CA2966005C (fr) 2014-10-31 2021-04-27 Abbvie Biotherapeutics Inc. Anticorps anti-cs1 et conjugues anticorps-medicament
US20180298447A1 (en) 2014-11-07 2018-10-18 Rheinisch Friedrich-Wilhelms-Universität Bonn Institut Für Rekonstruktive Neurobiologie Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation
US10005836B2 (en) 2014-11-14 2018-06-26 Novartis Ag Antibody drug conjugates
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
DK3750545T3 (da) 2014-11-17 2024-04-22 Cellectar Biosciences Inc Phospholipidetheranaloger som cancermålrettede lægemiddelbærere
WO2016081732A1 (fr) 2014-11-19 2016-05-26 Memorial Sloan-Kettering Cancer Center Thiénopyrimidines et utilisations de celles-ci
ES2772133T3 (es) 2014-11-20 2020-07-07 Merck Patent Gmbh Compuestos heteroarilo como inhibidores de IRAK y sus usos
WO2016087936A1 (fr) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Pyridinones substituées utilisées comme inhibiteurs de bromodomaines
US20180148789A1 (en) 2014-12-01 2018-05-31 University Of Southern California Methods for treating and assessing tumor invasion and metastasis
US10179125B2 (en) 2014-12-01 2019-01-15 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087490A1 (fr) 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de la voie pi3k
WO2016087488A1 (fr) 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Régime d'administration de dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués par un amino-alcool
CN107406508B (zh) 2014-12-04 2022-04-05 地中海治疗诊断有限公司 人源化的抗trop-2单克隆抗体及其应用
WO2016094273A1 (fr) 2014-12-08 2016-06-16 Dana-Farber Cancer Institute, Inc. Procédés de régulation à la hausse des réponses immunitaires à l'aide de combinaisons d'agents anti-rgmb et d'agents anti-pd-1
MY192690A (en) 2014-12-09 2022-09-01 Bayer Ag 1,3-thiazol-2-yl substituted benzamides
WO2016094309A1 (fr) 2014-12-10 2016-06-16 Myosotis Inhibition de la signalisation de tnf en immunothérapie du cancer
AU2015360260B2 (en) 2014-12-12 2021-10-28 Celcuity Inc. Methods of measuring ErbB signaling pathway activity to diagnose and treat cancer patients
EP3233127A1 (fr) 2014-12-15 2017-10-25 Bayer Pharma Aktiengesellschaft Conjugués anticorps-principe actif (adc) d'inhibiteurs de la ksp ayant des anticorps anti-tweakr aglycosylés
WO2016100619A2 (fr) 2014-12-17 2016-06-23 Rgenix, Inc. Traitement et diagnostic du cancer
WO2016097072A1 (fr) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Modulateurs des récepteurs des oestrogènes tétrahydro-pyrido[3,4-b]indole et utilisations associées
EP3233828B1 (fr) 2014-12-18 2020-03-04 F. Hoffmann-La Roche AG Modulateurs des recepteurs des oestrogenes et leurs utilisations
CN107406433A (zh) 2014-12-18 2017-11-28 豪夫迈·罗氏有限公司 用于治疗癌症的2,3‑二苯基色烯的衍生物
KR20170098869A (ko) 2014-12-18 2017-08-30 바이엘 파마 악티엔게젤샤프트 치환된 피리딜-시클로알킬-카르복실산, 그를 함유하는 조성물 및 그의 의학적 용도
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
JP6731942B2 (ja) 2014-12-19 2020-07-29 エピゲノミクスアーゲー ＣｐＧメチル化の検出方法及び癌の診断方法
WO2016100975A1 (fr) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
WO2016102493A1 (fr) 2014-12-22 2016-06-30 Bayer Pharma Aktiengesellschaft Inhibiteurs d'ezh2 de type imidazopyridine
WO2016102672A2 (fr) 2014-12-23 2016-06-30 Bergenbio As Composés pharmaceutiquement actifs
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
DE102014226903A1 (de) 2014-12-23 2016-06-23 Olympus Winter & Ibe Gmbh HF-Hilfsstoff, medizinisches System und Verfahren zum selektiven Behandeln von Krebsgewebe
EP3237417A1 (fr) 2014-12-23 2017-11-01 Bayer Pharma Aktiengesellschaft Imidazopyridazines 6-hydroxybenzofuranyl- et 6-alcoxybenzofuranyl-substituées
CA2972017C (fr) 2014-12-24 2019-06-11 Gilead Sciences, Inc. Composes isoindoline pour le traitement du vih
WO2016105532A1 (fr) 2014-12-24 2016-06-30 Gilead Sciences, Inc. Composés de pyrimidine fusionnés pour le traitement du vih
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
WO2016112245A1 (fr) 2015-01-08 2016-07-14 Hackensack University Medical Center Procédés ex vivo pour minimiser les risques et maximiser les effets bénéfiques d'une transfusion de sang allogénique et greffe de moelle
EP3242688B1 (fr) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Conjugués contenant du platine et ciblant cox-2, et utilisation de ces derniers dans le traitement de tumeurs et de cancers
JP6655249B2 (ja) 2015-01-23 2020-02-26 国立大学法人 鹿児島大学 Ｈｉｖ−１感染細胞殺傷剤及びその用途
KR20170103838A (ko) 2015-01-23 2017-09-13 컨플루언스 라이프 사이언시스, 인코포레이티드 염증 및 암의 치료를 위한 헤테로시클릭 itk 저해제
CA2974853C (fr) 2015-01-28 2023-02-21 Bayer Pharma Aktiengesellschaft Derives de 4h-pyrrolo[3,2-c]pyridin-4-one
HUE052821T2 (hu) 2015-01-30 2021-05-28 Oncoceutics Inc 7-benzil-4-(4-trifluormetil)benzil-1,2,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4H)-on és sói és azok terápiában történõ alkalmazása
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
ES2886577T3 (es) 2015-02-05 2021-12-20 Merck Patent Gmbh Compuestos macrólidos como inhibidores de irak1/4 y sus usos
BR112017014970B1 (pt) 2015-02-06 2022-11-16 Merck Patent Gmbh Macrociclos de piridazinona como inibidores de irak, seus usos, e composição farmacêutica
US20180028531A1 (en) 2015-02-12 2018-02-01 BeyondSpring Phamaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
EP3258941A4 (fr) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Traitement de cancers et de troubles de cellules souches hématopoïétiques privilégiés par interaction cxcl12-cxcr4
CA2976752C (fr) 2015-02-20 2019-12-17 Daiichi Sankyo Company, Limited Polytherapie pour traiter un cancer
PE20171789A1 (es) 2015-03-02 2017-12-28 Bristol Myers Squibb Co Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
CU20180011A7 (es) 2015-03-04 2018-06-05 Gilead Sciences Inc Composiciones farmacéuticas que comprenden compuestos derivados de diaminopirido (3,2-d) como moduladores de receptor de tipo toll
SG11201707240SA (en) 2015-03-09 2017-10-30 Bayer Pharma AG Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
TN2017000385A1 (en) 2015-03-09 2019-01-16 Bayer Healthcare Pharmaceuticals Inc Use of substituted 2,3-dihydroimidaz0[1,2-c]quinazolines.
EP3268044A2 (fr) 2015-03-11 2018-01-17 The Broad Institute Inc. Traitement sélectif de cancer dépendant de prmt5
EP3988106A1 (fr) 2015-03-13 2022-04-27 Ospedale San Raffaele S.r.l. Cellules t cd4+ productrices d'il-10 et leurs utilisations
US10946050B2 (en) 2015-03-16 2021-03-16 Imagilin Technology Llc Compositions comprising probiotics and methods of use thereof
WO2016149366A1 (fr) 2015-03-16 2016-09-22 The Johns Hopkins University Méthodes et compositions pour le traitement du cancer
US10195237B2 (en) 2015-03-16 2019-02-05 Imagilin Technology Llc Compositions and methods for treating inflammatory related diseases or conditions using Pediococcus acidilactici probiotics
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
EP3270966B1 (fr) 2015-03-20 2024-05-01 Syndax Pharmaceuticals Inc. Association d'un inhibiteur de l'histone désacétylase (hdac) avec un anticorps anti-pd-1 pour le traitement du cancer, la combinaison ne comprenant pas de 5-azacytidine.
US20180044418A1 (en) 2015-03-20 2018-02-15 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and vorinostat for treating cancer
WO2016153948A1 (fr) 2015-03-20 2016-09-29 Deuterx, Llc Polythérapie utilisant des 5-(benzyl)-5-deutéro-thiazolidine-2,4-diones oxy-substituées énantiopures, enrichies en deutérium pour le traitement de troubles médicaux
WO2016154082A2 (fr) 2015-03-23 2016-09-29 Tang Yao Procédés de culture de tissus primaires et de criblage de médicaments utilisant un sérum autologue et des fluides
AU2016238290B9 (en) 2015-03-25 2019-06-13 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
US10302629B2 (en) 2015-03-30 2019-05-28 University Of Maryland, Baltimore Compositions and methods for treating cancer by rational targeting of protein translation
PL3277691T3 (pl) 2015-04-02 2019-07-31 Gilead Sciences, Inc. Policykliczne związki karbamoilopirydonowe i ich zastosowanie farmaceutyczne
CN114149511A (zh) 2015-04-13 2022-03-08 辉瑞公司 靶向b细胞成熟抗原的嵌合抗原受体
WO2016166600A1 (fr) 2015-04-15 2016-10-20 Trojantec Technologies Ltd Administration de micro-arn à l'aide de microparticules de cellules souches mésenchymateuses
WO2016168721A1 (fr) 2015-04-17 2016-10-20 The Trustees Of The University Of Pennsylvania Dérivés dimères de la quinacrine utilisés en tant qu'inhibiteurs de l'autophagie pour la thérapie du cancer
IL255148B2 (en) 2015-04-29 2023-04-01 Radius Pharmaceuticals Inc 1901 rad for use in a method to inhibit a cancerous growth or induce tumor regression in a patient who is resistant to the drug and/or has cancer positive for an estrogen receptor alpha mutation
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
CA2984991A1 (fr) 2015-05-04 2016-11-10 Bionor Immuno As Schema posologique pour un vaccin contre le vih
WO2016177658A1 (fr) 2015-05-05 2016-11-10 Bayer Pharma Aktiengesellschaft Dérivés de cyclohexane à substitution amido
US10314854B2 (en) 2015-05-15 2019-06-11 University Of Iowa Foundation Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy
WO2016184963A1 (fr) 2015-05-19 2016-11-24 Innavirvax Traitement de patients souffrant d'une infection par le vih
WO2016184962A1 (fr) 2015-05-19 2016-11-24 Innavirvax Traitement de patients souffrant d'une infection par le vih
WO2016184973A1 (fr) 2015-05-19 2016-11-24 Innavirvax Traitement de patients souffrant d'une infection par le vih
US20160339030A1 (en) 2015-05-19 2016-11-24 University Of Maryland, Baltimore Treatment agents for inhibiting hiv and cancer in hiv infected patients
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
AU2016263579B2 (en) 2015-05-21 2020-12-03 Chemocentryx, Inc. CCR2 modulators
JP6816030B2 (ja) 2015-05-22 2021-01-20 アフィオス コーポレーション 組合せｈｉｖ治療薬
CN107531722B (zh) 2015-05-26 2020-07-17 豪夫迈·罗氏有限公司 杂环雌激素受体调节剂及其用途
CN104892648A (zh) 2015-05-27 2015-09-09 天津工业大学 一种负载抗肿瘤药物的靶向金属有机骨架的制备及用途
EP3304080A1 (fr) 2015-05-28 2018-04-11 Bayer Pharma Aktiengesellschaft Procédé permettant une stratification des patients atteints de mélanome par détermination de la consommation d'oxygène, des niveaux de ppargc1a, de ppargc1b et de mitf
WO2016196471A1 (fr) 2015-06-02 2016-12-08 Cooper Human Systems Llc Procédés et compositions pour le traitement d'une infection par le vih
WO2016197009A1 (fr) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles pour le traitement de maladies liées à la démyélinisation
NZ737542A (en) 2015-06-05 2019-09-27 Miragen Therapeutics Inc Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
WO2016198322A1 (fr) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles à titre d'inhibiteurs de midh1
CA2986441A1 (fr) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Therapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases
CA2989269C (fr) 2015-06-15 2020-09-22 Robert Yongxin Zhao Lieurs hydrophiles pour la conjugaison d'un agent cytotoxique ou d'une molecule chromophore a une molecule de fixation
WO2016205566A1 (fr) 2015-06-16 2016-12-22 The Regents Of The University Of California Anticorps spécifiques anti-fzd7 et vaccins pour traiter le cancer et réguler la fonction de cellules souches
US10766962B2 (en) 2015-06-16 2020-09-08 The Regents Of The University Of California FZD7 specific antibodies and vaccines to treat cancer and control stem cell function
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
WO2016202758A1 (fr) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués
WO2016202756A1 (fr) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués
CN116712552A (zh) 2015-06-19 2023-09-08 波士顿大学托管委员会 用于治疗疱疹病毒诱导的病况的方法和组合物
WO2015151079A2 (fr) 2015-06-20 2015-10-08 Hangzhou Dac Biotech Co, Ltd Analogues d'auristatine et leur conjugués avec des molécules de liaison cellulaire
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
EP3313523A2 (fr) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Conjugués ciblés d'inhibiteurs de ksp
CN107921145A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 Ksp抑制剂与抗‑tweakr抗体的抗体药物缀合物（adc）
CN107921146A (zh) 2015-06-23 2018-04-17 拜耳医药股份有限公司 纺锤体驱动蛋白(ksp)抑制剂与抗‑cd123的抗体的抗体药物缀合物(adc)
US20190070154A1 (en) 2015-06-24 2019-03-07 Duke University New methods of use for an anti-diarrhea agent
EP3313388A4 (fr) 2015-06-24 2019-05-15 Duke University Modulateurs chimiques des voies de signalisation et utilisation thérapeutique
CN107921050A (zh) 2015-06-29 2018-04-17 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗血液学恶性肿瘤的方法
EP3313433A4 (fr) 2015-06-29 2019-01-02 Syndax Pharmaceuticals Inc. Association d'un inhibiteur de l'histone désacétylase (hdac) avec un anticorps anti-pdl-1 pour le traitement du cancer
WO2017003995A1 (fr) 2015-06-29 2017-01-05 Merck Patent Gmbh Composés inhibiteurs de tbk/ikkε et leurs utilisations
JP2018521058A (ja) 2015-06-29 2018-08-02 アブラクシス バイオサイエンス， エルエルシー ナノ粒子ｍＴＯＲ阻害剤併用治療を使用して固形腫瘍を処置する方法
UY36758A (es) 2015-06-30 2016-12-30 Glaxosmithkline Ip No 2 Ltd Inhibidores del potenciador del homólogo zeste 2
US10925852B2 (en) 2015-06-30 2021-02-23 The Trustees Of Columbia University In The City Of New York Talc-bound compositions and uses thereof
JP6700321B2 (ja) 2015-07-04 2020-05-27 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の特異的共役体
US10179123B2 (en) 2015-07-07 2019-01-15 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as mIDH1 inhibitors
US20180371550A1 (en) 2015-07-08 2018-12-27 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
CA2989651A1 (fr) 2015-07-09 2017-01-12 Merck Patent Gmbh Derives de pyrimidine servant d'inhibiteurs de la btk, et leurs utilisations
WO2017005711A1 (fr) 2015-07-09 2017-01-12 Bayer Pharma Aktiengesellschaft Dérivés de benzodiazépine substitués par du phosphore et du soufre
US10292961B2 (en) 2015-07-15 2019-05-21 Hangzhou Dac Biotech Co., Ltd. Disulfur bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017009325A1 (fr) 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles en tant qu'inhibiteurs de midh1
EP3121166A1 (fr) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Imidazoles condensés comme inhibiteurs midh1
GB201512869D0 (en) 2015-07-21 2015-09-02 Almac Diagnostics Ltd Gene signature for minute therapies
WO2017019767A1 (fr) 2015-07-27 2017-02-02 Myosotis, Llc Inhibition de cxcl12 dans l'immunothérapie anticancéreuse
JP2018523705A (ja) 2015-07-28 2018-08-23 ベータ・キャット・ファーマシューティカルズ・インコーポレイテッド アントラセン−９，１０−ジオンジオキシム化合物プロドラッグ及びその使用
PL3330267T3 (pl) 2015-07-29 2022-04-04 Shionogi&Co., Ltd. Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
AU2016300128B2 (en) 2015-07-29 2022-03-17 Onk Therapeutics Limited Modified natural killer cells and natural killer cell lines having increased cytotoxicity
EP3124609A1 (fr) 2015-07-29 2017-02-01 IFOM Fondazione Istituto Firc di Oncologia Molecolare Oligonucléotides thérapeutiques
LT3317301T (lt) 2015-07-29 2021-07-26 Novartis Ag Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
EP3316902A1 (fr) 2015-07-29 2018-05-09 Novartis AG Polythérapies comprenant des molécules d'anticorps contre tim -3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3735977A1 (fr) 2015-07-31 2020-11-11 Vascular Biogenics Ltd. Protéine 2 contenant le domaine de sperme motile et cancer
AU2016302243B2 (en) 2015-08-03 2019-07-11 Quadriga Biosciences, Inc. Beta-substituted Beta-amino acids and analogs as chemotherapeutic agents and uses thereof
JP2018525375A (ja) 2015-08-05 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト １ｈ−ピロール−３−アミン類
WO2017023994A1 (fr) 2015-08-06 2017-02-09 Yale University Composés de recrutement d'anticorps à base de petites molécules pour le traitement du cancer
WO2017027379A1 (fr) 2015-08-07 2017-02-16 Thomas Helledays Stiftelse För Medicinsk Forskning Procédé pour diagnostiquer un cancer ou une thrombose associée à un cancer en mesurant les concentrations plasmatiques de h3cit
CN108136023B (zh) 2015-08-12 2021-07-27 北卡罗莱纳州立大学 血小板膜包覆的药物递送系统
WO2017025493A1 (fr) 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Inhibiteurs quinoléine d'ezh2
WO2017031041A1 (fr) 2015-08-17 2017-02-23 Channel Therapeutics, Inc. Aminobenzoboroxoles fonctionnalisés
EP3133165A1 (fr) 2015-08-17 2017-02-22 F. Hoffmann-La Roche AG Procédés pour la personnalisation d'une thérapie de cancer de patient avec des composés anti-angiogéniques
GB201514756D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
WO2017034234A1 (fr) 2015-08-21 2017-03-02 서울대학교 산학협력단 Formulation composite pour le traitement du cancer présentant une résistance à un inhibiteur de l'histone désacétylase
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
JP2018525412A (ja) 2015-08-26 2018-09-06 ギリアード サイエンシーズ， インコーポレイテッド 重水素化トール様受容体調節因子
WO2017035453A1 (fr) 2015-08-26 2017-03-02 The Johns Hopkins University Compositions et méthodes de traitement de tumeurs solides
CN114288294A (zh) 2015-09-01 2022-04-08 布罗德研究所股份有限公司 用于治疗或者预防血液癌症的化合物和方法
EP3345002A4 (fr) 2015-09-02 2019-05-08 Syndax Pharmaceuticals Inc. Sélection de patients pour une polythérapie
US10588985B2 (en) 2015-09-02 2020-03-17 Wayne State University Compositions and methods relating to RAD6 inhibition
JP6971970B2 (ja) 2015-09-03 2021-11-24 エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics, Inc. ペプチド模倣大環状分子およびその使用
DE102015012049A1 (de) 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
EP3350316B1 (fr) 2015-09-15 2024-05-08 Stichting Radboud universitair medisch centrum PROCÉDÉ AMÉLIORÉ POUR L'EX VIVO EXPANSION DE CD34+HSPCs DANS DES CELLULES NK UTILISANT UN ANTAGONISTE DU RÉCEPTEUR DES HYDROCARBURES DU GROUPE ARYLE
DE102015012050A1 (de) 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
ES2911888T3 (es) 2015-09-18 2022-05-23 Merck Patent Gmbh Compuestos de heteroarilo como inhibidores de IRAK y usos de los mismos
ES2911524T3 (es) 2015-09-18 2022-05-19 Merck Patent Gmbh Compuestos heteroarilo como inhibidores de IRAK y sus usos
EP3349893A4 (fr) 2015-09-20 2019-09-11 Air Cross Inc. Ozonolyse pour activation de composés et dégradation d'ozone
AU2016328619B2 (en) 2015-09-21 2020-07-16 Opna Bio SA Heterocyclic compounds and uses thereof
WO2017050849A1 (fr) 2015-09-21 2017-03-30 Ifom Fondazione Istituto Firc Di Oncologia Molecolare Nouvelles stratégies thérapeutiques contre la leucémie
WO2017053823A1 (fr) 2015-09-25 2017-03-30 Pharmacyclics Llc Traitement à l'aide d'inhibiteurs d'hdac et d'immunothérapie
US20180271849A1 (en) 2015-09-29 2018-09-27 Kangpu Biopharmaceuticals, Ltd. Pharmaceutical composition and application thereof
ES2797900T3 (es) 2015-09-30 2020-12-04 Gilead Sciences Inc Compuestos y combinaciones para el tratamiento del VIH
WO2017055313A1 (fr) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Composés azole amido-substitués
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
WO2017055316A1 (fr) 2015-10-01 2017-04-06 Bayer Pharma Aktiengesellschaft Composés azole à substitution amido
US10544156B2 (en) 2015-10-02 2020-01-28 Pierre Fabre Medicament Hemi-synthetic trilobine analogs for use as a drug
EP3355871A1 (fr) 2015-10-02 2018-08-08 Gilead Sciences, Inc. Combinaisons de l'inhibiteur de btk gs-4059 avec des inhibiteurs choisis parmi un inhibiteur de jak, d'ask1, de brd et/ou de mmp9 pour traiter le cancer, les troubles allergiques, les maladies auto-immunes ou les maladies inflammatoires
UA123905C2 (uk) 2015-10-09 2021-06-23 Бьорінгер Інгельхайм Інтернаціональ Гмбх Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53
WO2017060322A2 (fr) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Conjugué anticorps-médicament (adc) inhibiteur de ptefb
WO2017063966A1 (fr) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Composés 2-(1h-pyrazol-1-yl)-benzothiazole substitués
CN105288648B (zh) 2015-10-14 2018-11-06 东南大学 一种亲水性药物的磷脂化合物、其药物组合物及应用
WO2017063959A1 (fr) 2015-10-15 2017-04-20 Bayer Pharma Aktiengesellschaft Dérivés de la benzodiazépine n-sulfoximinophényl-substitués utilisés comme inhibiteurs de protéines bet
TW201732037A (zh) 2015-10-15 2017-09-16 安瑟吉納西斯公司 自然殺手細胞及ilc3細胞及其用途
CA3002541A1 (fr) 2015-10-19 2017-04-27 Dana-Farber Cancer Institute, Inc. Polymerase q utilisee comme cible dans des cancers deficients en rh
JP2018538247A (ja) 2015-10-23 2018-12-27 第一三共株式会社 Ａｍｌを処置することに用いるための医薬組成物およびそれを必要とする対象においてａｍｌを処置する方法
US20170115275A1 (en) 2015-10-23 2017-04-27 Arizona Board Of Regents On Behalf Of Arizona State University Engineered substrates for high-throughput generation of 3d models of tumor dormancy, relapse and micrometastases for phenotype specific drug discovery and development
JP6855472B2 (ja) 2015-10-23 2021-04-07 第一三共株式会社 がんを治療するためのｍｄｍ２阻害剤の投与計画
EP3368687B1 (fr) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions et procédés de ciblage de variations de séquences spécifiques du cancer
EP3368689B1 (fr) 2015-10-28 2020-06-17 The Broad Institute, Inc. Compositions d'évaluation et de modulation des réponses immunitaires à l'aide de signatures génétiques de cellules immunitaires
WO2017075451A1 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de pou2af1
WO2017075465A1 (fr) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions et procédés d'évaluation et de modulation des réponses immunitaires par détection et ciblage de gata3
JP2019500893A (ja) 2015-11-03 2019-01-17 ヤンセン バイオテツク，インコーポレーテツド Ｐｄ−１及びｔｉｍ−３に特異的に結合する抗体及びそれらの使用
AU2016349632A1 (en) 2015-11-07 2018-05-24 Multivir Inc. Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer
CN105457038A (zh) 2015-11-09 2016-04-06 东南大学 一种速释型药物磷脂化合物及其药物组合物
JP6924495B2 (ja) 2015-11-10 2021-08-25 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 自己免疫疾患およびがんを処置するための組成物および方法
CN108697775B (zh) 2015-11-12 2023-05-09 霍欧奇帕生物科技有限公司 作为癌症疫苗的沙粒病毒颗粒
US11660340B2 (en) 2015-11-18 2023-05-30 Chugai Seiyaku Kabushiki Kaisha Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
EP3440579A4 (fr) 2015-11-24 2020-03-25 Klaritos, Inc. Modèle innovant de livraison, de traitement et de paiement pour des médicaments spécialisés
WO2017093447A1 (fr) 2015-12-01 2017-06-08 Genmab B.V. Anticorps anti-récepteur de mort et procédés d'utilisation associés
US10654818B2 (en) 2015-12-03 2020-05-19 Bayer Pharma Aktiengesellschaft Furane derivatives as inhibitors of ATAD2
WO2017096246A1 (fr) 2015-12-03 2017-06-08 Temple University-Of The Commonwealth System Of Higher Education Modulation de nad+ et voies métaboliques de nad+ pour le traitement de maladies
AU2016363113A1 (en) 2015-12-03 2018-06-07 Alfred Health Monitoring treatment or progression of myeloma
CN106821965A (zh) 2015-12-04 2017-06-13 中国科学院大连化学物理研究所 一种维甲酸多药共递送纳米粒溶液及其制备和应用
CA3006235A1 (fr) 2015-12-04 2017-06-08 Boehringer Ingelheim International Gmbh Polypeptides biparatopiques ayant un effet antagoniste sur la signalisation wnt dans des cellules tumorales
MX2018006953A (es) 2015-12-09 2019-05-16 Univ Wien Med Compuestos de platino funcionalizados con monomaleimida para la terapia del cancer.
US10969392B2 (en) 2015-12-10 2021-04-06 Vanderbilt University Methods and systems for predicting response to immunotherapies for treatment of cancer
PE20181451A1 (es) 2015-12-15 2018-09-12 Gilead Sciences Inc Anticuerpos neutralizadores del virus de inmunodeficiencia humana
JP2019504826A (ja) 2015-12-16 2019-02-21 バイエル ファーマ アクチエンゲゼルシャフト ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類
EP3399989B1 (fr) 2015-12-16 2023-08-09 Merck Sharp & Dohme LLC Anticorps anti-lag3 et fragments de fixation à l'antigène
MX2018007421A (es) 2015-12-17 2018-08-15 Gilead Sciences Inc Compuestos inhibidores de quinasa de union a tank.
US20180371093A1 (en) 2015-12-17 2018-12-27 Novartis Ag Antibody molecules to pd-1 and uses thereof
SG10202001146PA (en) 2015-12-17 2020-03-30 Merck Patent Gmbh Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
US10894784B2 (en) 2015-12-18 2021-01-19 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
EP3389711A1 (fr) 2015-12-18 2018-10-24 Novartis AG Anticorps ciblant cd32b et leurs procédés d'utilisation associés
US20200268720A1 (en) 2015-12-22 2020-08-27 Glaxosmithkline Llc Methods of use of a class iia hdac inhibitor
EP3405478A4 (fr) 2015-12-23 2019-10-30 Moonshot Pharma LLC Procédés d'induction d'une réponse immunitaire par inhibition de la dégradation des arnm non-sens
BR112018013094A2 (pt) 2015-12-28 2018-12-11 Merck Patent Gmbh combinação de inibidor de hdac e anticorpo de anti-pd-l1 para o tratamento de câncer ovariano
US10189797B2 (en) 2015-12-30 2019-01-29 Duke University Chemical modulators of immune checkpoints and therapeutic use
US11834675B2 (en) 2015-12-30 2023-12-05 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
WO2017120204A2 (fr) 2016-01-05 2017-07-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combinaison d'un inhibiteur d'histone désacétylase et d'une immunothérapie
EP3805376A1 (fr) 2016-01-08 2021-04-14 Replimune Limited Virus modifié
CA3010883A1 (fr) 2016-01-11 2017-07-20 The Rockefeller University Methodes pour le traitement de troubles associes a des cellules suppressives derivees de cellules myeloides
WO2017121684A1 (fr) 2016-01-14 2017-07-20 Bayer Pharma Aktiengesellschaft 2-(morpholin-4-yl)-1,7-naphthyridines substituées en 5
US11963520B2 (en) 2016-01-19 2024-04-23 Celgene Corporation Transgenic mouse expressing human cereblon
CN108472259A (zh) 2016-01-19 2018-08-31 詹森药业有限公司 包含btk抑制剂的配制品/组合物
WO2017132541A1 (fr) 2016-01-27 2017-08-03 University Of Maryland, Baltimore Procédé de surveillance du cancer et de régulation de la sémaphorine 4d pour améliorer les régimes immunothérapeutiques anti-cancéreux
KR20180104122A (ko) 2016-01-28 2018-09-19 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 면역요법을 향상시키기 위한 히스톤 데아세틸라제 저해제의 용도
HUE054225T2 (hu) 2016-01-29 2021-08-30 Epigenomics Ag Módszerek a daganatból származó DNA CPG-metilációjának kimutatására vérmintákban
AU2017215096A1 (en) 2016-02-01 2018-08-09 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
GB201601773D0 (en) 2016-02-01 2016-03-16 Renishaw Plc Method
KR20180101603A (ko) 2016-02-01 2018-09-12 바이엘 파마 악티엔게젤샤프트 코판리십 바이오마커
WO2017136342A1 (fr) 2016-02-02 2017-08-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fulvestrant induisant la lyse cytotoxique à médiation immunitaire des cellules cancéreuses
US11078277B2 (en) 2016-02-02 2021-08-03 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer
CA3209672A1 (fr) 2016-02-04 2016-04-21 Hangzhou Dac Biotech Co., Ltd. Lieurs de conjugaison specifique, immunoconjugues specifiques de ceux-ci, procedes de fabrication et utilisations desdits conjugues de ceux-ci
JP7148403B2 (ja) 2016-02-05 2022-10-05 バイエル・ファルマ・アクティエンゲゼルシャフト 癌患者の層別化および癌治療のための化合物、組成物および方法
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
CA3011372A1 (fr) 2016-02-10 2017-08-17 Immunomedics, Inc. La combinaison inhibiteurs abcg2-sacituzumab govitecan (immu-132) surmonte la resistance a sn-38 dans les cancers exprimant trop-2
WO2017143237A1 (fr) 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Augmentation de l'expression de gènes régulés par l'interféron à l'aide de combinaisons d'inhibiteurs de l'histone désacétylase et de médicaments immunomodulateurs
WO2017143035A2 (fr) 2016-02-17 2017-08-24 The Penn State Research Foundation Méthode et utilisation thérapeutique du gène ping et autres gènes ou produits géniques avec lesquels ping interagit pour le pronostic et le traitement des néoplasies hématologiques
CA3015241A1 (fr) 2016-02-22 2017-08-31 Onxeo Polytherapies comprenant des agents immuno-oncologiques et du belinostat
JP2019511919A (ja) 2016-02-23 2019-05-09 ブローディ，チャヤ がん幹細胞の作製およびその使用
US20170247690A1 (en) 2016-02-25 2017-08-31 Agenovir Corporation Oncoviral treatment with nuclease and chemotherapeutic
WO2017148995A1 (fr) 2016-03-04 2017-09-08 Bayer Pharma Aktiengesellschaft 1-(pyrimidin-2-yl)-1h-indazoles possédant une activité d'inhibition de la kinase bub1
WO2017152062A1 (fr) 2016-03-04 2017-09-08 Gilead Sciences, Inc. Compositions et combinaisons d'inhibiteurs de l'autotaxine
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
WO2017153220A1 (fr) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-méthoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
WO2017156147A1 (fr) 2016-03-08 2017-09-14 The Board Of Regents For Oklahoma State University Office Of Intellectual Property Management Technology Development Center Composés alimentaires de stimulation immunitaire permettant la lutte contre et la prévention de maladie
CN109310738A (zh) 2016-03-14 2019-02-05 克罗米科股份有限公司 用于治疗癌症的组合物和方法
WO2017157418A1 (fr) 2016-03-15 2017-09-21 Bayer Pharma Aktiengesellschaft Combinaison d'inhibiteurs de mknk1
WO2017160717A2 (fr) 2016-03-15 2017-09-21 Memorial Sloan Kettering Cancer Center Méthode de traitement de maladies à l'aide de modulateurs de kinases
US20170268001A1 (en) 2016-03-16 2017-09-21 The University Of Chicago Rnas with tumor radio/chemo-sensitizing and immunomodulatory properties and methods of their preparation and application
EP3219329A1 (fr) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinaisons de copanlisib
WO2017157991A1 (fr) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft 1-alkyl-pyrazoles et 1-alkyl-indazoles utilisés en tant qu'inhibiteurs de bub1 pour le traitement de maladies hyperprolifératives
WO2017157992A1 (fr) 2016-03-18 2017-09-21 Bayer Pharma Aktiengesellschaft Pyrazoles annelés utilisés en tant qu'inhibiteurs de kinase bub1 pour le traitement de troubles prolifératifs
JP6937775B2 (ja) 2016-03-18 2021-09-22 プロセプト バイオロボティクス コーポレイション 出血閉鎖組織体積における止血のための低侵襲方法およびシステム
US20170273926A1 (en) 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
CN105949114A (zh) 2016-06-27 2016-09-21 山东川成医药股份有限公司 一种西达本胺的合成方法
CN106866571B (zh) 2017-01-20 2018-06-29 中国药科大学 杂环脲类化合物及其药物组合物和应用
KR102125661B1 (ko) 2017-02-13 2020-06-22 강푸 바이오파마슈티칼즈 리미티드 전립선암 치료용 조합, 약학 조성물 및 치료 방법
CN106916101B (zh) 2017-02-15 2020-05-01 聚缘（上海）生物科技有限公司 Nampt/hdac双靶点抑制剂及其制备方法
CN107011238B (zh) 2017-03-14 2020-05-01 北京化工大学 一类组蛋白去乙酰化酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
WO2017197153A8 (fr) 2018-11-01
IL262814B2 (en) 2024-01-01
BR112018073329A2 (pt) 2019-02-26
MX2018013591A (es) 2019-11-07
JP2022017296A (ja) 2022-01-25
TWI808055B (zh) 2023-07-11
KR20220123743A (ko) 2022-09-08
CA3023549A1 (fr) 2017-11-16
AU2017263478B2 (en) 2022-04-21
TW201740943A (zh) 2017-12-01
CN109562177A (zh) 2019-04-02
IL262814A (en) 2018-12-31
MX2022001834A (es) 2022-03-17
US10287353B2 (en) 2019-05-14
JP7013387B2 (ja) 2022-01-31
US20200172621A1 (en) 2020-06-04
KR20190022521A (ko) 2019-03-06
US20170327582A1 (en) 2017-11-16
JP7190549B2 (ja) 2022-12-15
IL262814B1 (en) 2023-09-01
KR102469268B1 (ko) 2022-11-22
WO2017197153A1 (fr) 2017-11-16
US10385130B2 (en) 2019-08-20
EP3454844B1 (fr) 2024-07-03
EP3454844A4 (fr) 2020-01-15
AU2017263478A1 (en) 2018-11-29
JP2019519498A (ja) 2019-07-11
AU2022202392A1 (en) 2022-05-05
EP3454844A1 (fr) 2019-03-20
US20180355042A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
MA44991A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-1
MA44990A (fr) Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
DK3559009T3 (da) Sammensætninger og metoder til inhibition af arginaseaktivitet
MA46481A (fr) Compositions d'oligonucléotides et méthodes associées
MA51066A (fr) Inhibiteurs d'intégrine
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA43823A (fr) Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation
MA42925A (fr) Anticorps anti-tigit et méthodes d'utilisation
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
DK3578547T3 (da) Sulfonylureaer og relaterede forbindelser og brug af samme
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
JP2018172409A5 (ja) １５−ｈｅｐｅを含む組成物および同組成物を使用する方法
MA46193A (fr) Inhibiteurs hétéroaryles de pad4
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
DE102016116153A8 (de) Wirksame verfolgung von orten persönlicher vorrichtungen
DK3388427T3 (da) Derivater af dolastatin 10 og auristatiner
MA47305A (fr) Inhibiteurs bicycliques d'histone désacétylase
MA43361A (fr) Composition pour le soin et la protection de cultures
MA46422A (fr) Oligonucléotides modifiés et méthodes d'utilisation
DK3501268T3 (da) Regenerering af planter i tilstedeværelse af histondeacetylase hæmmere
MA47669A (fr) Structure cristalline de gremlin-1 et anticorps inhibiteur